Propranolol Rescue of Prolonged Labor (PROPEL): A Randomized, Double-blind, Placebo-controlled Multicenter Investigation of Propranolol's Effect on Cesarean Delivery Rate Among Women With Prolonged Labor
Phase: PHASE3
Conditions: Pregnancy, Prolonged
Sponsor: Lisa Levine

 
7.26.21  
 
NCT04299438 
 
Propranolol Rescue of Prolonged Labor (PROPEL) 
A randomized, double-blind, placebo-controlled multicenter investigation of propranolol’s effect on 
cesarean delivery rate among women with prolonged labor 
 
 
Principal Investigator:  
Lisa D. Levine, MD, MSCE 
 
 
 
 
Assistant Professor 
 
 
 
 
Division of Maternal Fetal Medicine 
 
 
 
 
Department of Obstetrics and Gynecology 
 
 
 
 
3400 Spruce St 
 
 
 
 
2 Silverstein 
 
 
 
 
Philadelphia, PA 19104 
 
 
 
 
 
 
Sub-Investigator(s): 
 
Jennifer McCoy, MD 
 
 
 
 
Clinical Fellow 
 
 
 
 
Division of Maternal Fetal Medicine 
 
 
 
 
Department of Obstetrics and Gynecology 
 
 
 
 
 
 
 
 
 
 
Study Drug/Study Device: 
Propranolol hydrochloride 
 
 
 
 
 
 
 
 

 
7.26.21  
 
NCT04299438 
 
LIST OF ABBREVIATIONS 
 
AE 
Adverse event 
DSMB 
Data safety monitoring board 
CD 
Cesarean delivery 
EFM 
Electronic fetal monitoring 
GBS 
Group B streptococcus 
HIE 
Hypoxic ischemic encephalopathy 
ICN 
Intensive care nursery  
ICU 
Intensive care unit 
IDS 
Investigational drug service 
IOL 
Induction of labor 
IRB 
Investigational review board 
IV 
Intravenous 
IVH 
Intraventricular hemorrhage  
NEC 
Necrotizing enterocolitis 
OB 
Obstetric 
RDS 
Respiratory distress syndrome 
SAE 
Serious adverse event 
VTE 
Venous thromboembolism  
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
7.26.21  
 
NCT04299438 
 
STUDY SCHEMA 
Screening 
Enrollment 
 
 
Allocation 
 
 
Time point 1 
 
 
 
Time Point 2  
 
 
 
 
Follow up 
 
 
Analysis
Post-discharge from hospital, review of medical records for woman and 
infant; abstraction of relevant clinical data points  
Final analysis 
Total n=326:  Obtain informed consent. Screen potential participants by 
inclusion and exclusion criteria; obtain history, document. 
Delivery 
Postpartum and neonatal management per usual care 
Administer Dose 1 of study drug 
Continue to monitor maternal vital signs and fetal monitoring 
Labor management per usual care 
Randomize 
Arm 2: Placebo 
163 participants 
Arm 1: Propranolol 
163 participants 
If meets study criteria, administer Dose 2 of study drug >2hrs after Dose 1 
Continue to monitor maternal vital signs and fetal monitoring 
Labor management per usual care 

 
7.26.21  
 
NCT04299438 
 
Study Summary 
Title 
Propranolol rescue of prolonged labor 
Short Title 
PROPEL 
Methodology 
Double-blind randomized controlled trial 
Study duration 
24 Months 
Study Center (s) 
Multi-center: Hospital of the University of 
Pennsylvania and Pennsylvania Hospital 
Objective 
To compare cesarean delivery (CD) rates in 
women given IV propranolol versus placebo for 
treatment of prolonged labor.  
Number of Subjects 
326 
Diagnosis and Main Inclusion Criteria 
Meets criteria for prolonged labor:  
1. cervical dilation <6 cm after ≥12 hours with 
ruptured membranes and receiving oxytocin 
OR  
2. cervical dilation >6 cm and <1 cm dilation 
change over ≥2 hours with ruptured 
membranes and receiving oxytocin  
AND 
>16 years old, > 36 weeks gestation; Singleton 
gestation in vertex presentation; non anomalous 
fetus 
Study Product (s), Dose, Route, Regimen 
IV Propranolol – 2mg; one possible repeat dose 
≥2 hours later  
Normal saline placebo- 2 mL; one possible repeat 
dose ≥2 hours later  
Duration of administration 
Eligible for maximum of one repeat dose ≥2 
hours after first until reaches 10cm dilation 
Primary Outcome 
Cesarean delivery  
Statistical methodology 
Intention to treat analysis, chi-square test for 
categorical variables, two-sample t-test for 
continuous variables 
 
 
 
 
 
 
 
 

 
7.26.21  
 
NCT04299438 
 
1 
BACKGROUND AND RATIONALE 
1.1 Condition Background 
Since the 1980’s, the rate of cesarean delivery (CD) in the US has climbed dramatically to its current rate 
around 33% of all deliveries.1 While CD can be a life-saving procedure for both mother and baby, it also 
carries significant risks, both immediate and in future pregnancies. Currently, 34% of all CDs performed 
in the United States are for labor arrest, making labor arrest the most common indication for primary 
cesarean delivery.1 The etiology of labor arrest is thought to be related to 3 primary factors – 
contraction strength or frequency, the size and position of the fetus, and the shape and space in the 
pelvis. Of these three etiologies, the most common cause of protracted labor is inadequate contraction 
strength and/or frequency. Additionally, this is the only truly modifiable etiology of labor arrest, so it is 
an important target for therapeutic intervention. Current standards for clinical management of labor 
arrest included artificial rupture of membranes and administering oxytocin to increase contraction 
strength and frequency. Even with these interventions, attempts to resolve labor arrest still often fail, 
up to 50% of the time.1 There is a great clinical need for additional strategies to treat labor arrest and 
reduce the associated rates of CD and maternal morbidity. While some small prior studies have 
identified treatment with propranolol to have possible benefit in management of labor dystocia, others 
have not found the same results, likely due to heterogeneous populations being evaluated. Propranolol 
warrants further study to evaluate its effectiveness as an intervention for treatment of labor arrest. 
1.2 Study Agent(s)/Devices Background and Associated Known Toxicities  
Propranolol is a nonselective β-adrenergic receptor blocking agent that specifically competes with β-
adrenergic receptor stimulating agents for available receptor sites, thereby decreasing chronotropic, 
inotropic, and vasodilator responses to β-adrenergic stimulation. β1 adrenergic receptors are found 
primarily in the heart, where blockade of cardiac β-adrenergic receptors leads to a decrease in the 
activity of pacemaker cells and a decrease in A-V nodal conduction velocity. These actions lead to 
antiarrhythmic activity and control of ventricular rate. β2 adrenergic receptors are found predominantly 
in smooth muscle, including vascular, bronchial, gastrointestinal, and uterine smooth muscle, where 
blockade of these receptors results in smooth muscle constriction.  
Propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first degree 
block; 3) bronchial asthma; and 4) in patients with known hypersensitivity to propranolol hydrochloride. 
Adverse events reported with use of propranolol include bradycardia, hypotension, congestive heart 
failure, heart block, cardiac arrest, dyspnea, and cutaneous ulcers.  
Early in vitro studies in the 1960’s identified the presence of β receptors on the human uterus. In 1966, 
the first clinical studies demonstrated that administering IV propranolol to pregnant women at term 
caused increased contraction strength and frequency.2 In 1996, the first clinical trial attempting to utilize 
propranolol as a labor augmentation agent was published. In this study, the authors demonstrated a 
nearly 50% reduction in the rate of CD among women with labor dystocia who were given IV 
propranolol compared to women with labor dystocia given placebo.3 Subsequently, there have been 5 
additional studies examining propranolol as labor medication.4-8 One non-blinded RCT administered 2mg 

 
7.26.21  
 
NCT04299438 
 
of IV propranolol to nulliparous women admitted for labor or for induction of labor (IOL).8 Notably, 
these patients did not have any diagnosis of dystocia, and the medication was given as an adjunct to 
normal labor management. The CD rate was quite low overall in this study, and there was no significant 
difference between the two groups. Another study was a double-bind RCT of women with arrest of 
dilation, with an unchanged cervical exam for 2 hrs anywhere from 2-7cm during labor.7 Patients 
received 2mg IV propranolol with a repeat dose in 1 hr if unchanged, vs placebo. This study also had a 
low overall CD rate, with no difference between groups. Two additional studies have evaluated the use 
of propranolol as an induction agent.4,6 Both were done in Iran where the induction protocol is quite 
different than in the US. The first study, which included only nulliparous patients, showed no difference 
in CD rate but a 2.5 hour shorter time to delivery; the second study found a significant difference in CD 
rate from 40 to 20% in the PO propranolol group. Finally, one additional study evaluated the 
administration of propranolol to women with arrest of active phase but with a low rate of oxytocin 
usage – 28% of propranolol the group versus 60% of placebo group.5 Ultimately this study showed no 
difference in the CD rate, but given the low use of oxytocin in this study, it is less applicable to most 
obstetric practice. In the 7 total published clinical trials referenced above, there were no reported safety 
issues, side effects, or incidences of worse maternal or neonatal outcomes in those patients who 
received propranolol. Each of the 7 trials demonstrated the safety of administering this medication in 
labor. 
The dose regimen in our proposal (2mg IV followed by up to one repeat dose ≥2 hours later) is based on 
previous clinical trials of propranolol used in labor, as well as current accepted practice and propranolol 
dosing regimens used in other clinical scenarios. We believe that IV is more appropriate than PO in this 
context as the onset of action and half-life of the IV formulation is shorter than PO and more 
appropriate for the time frame of intended effect. According to the propranolol package insert, the 
usual dose is 1 to 3 mg, and the rate of administration should not exceed 1 mg per minute to diminish 
the possibility of lowering blood pressure. According to the labeling, a second dose may be given after 
two minutes. Our proposed protocol will be compliant with this recommendation.  
1.3 Rationale 
There is biologic plausibility for the role of propranolol in labor management. Prior studies have 
suggested possible benefit, but they have been small and heterogeneous with mixed results. The utility 
of propranolol in management of prolonged labor has not been established. This medication warrants 
further study to evaluate its effectiveness as an intervention for treatment of labor arrest. 
2 
STUDY AIMS 
2.1 AIM 1: To compare CD rates among women given IV propranolol versus placebo for 
treatment of prolonged labor.  
2.2 Endpoints 
2.2.1 
Primary Endpoint 
• 
Mode of delivery (cesarean versus vaginal) 
2.2.2 
Secondary Endpoints 
• 
Time (hours) from start of labor/IOL to delivery 

 
7.26.21  
 
NCT04299438 
 
• 
Time (hours) from study drug administration to delivery 
• 
Time (hours) from start of second stage of labor to delivery 
• 
Indication for CD 
• 
Operative vaginal delivery 
• 
Cumulative and maximum dose of intrapartum oxytocin received 
• 
Postpartum hemorrhage 
• 
Maternal blood transfusion 
• 
Endometritis 
• 
Chorioamnionitis 
• 
Wound infection 
• 
Other composite maternal morbidity: VTE, Hysterectomy, ICU admission, 
Maternal readmission within 7 days and 4 weeks, Maternal death 
• 
ICN adm > 48 hours 
• 
Composite neonatal outcome:, neonatal blood transfusion, HIE, IVH grade 3 or 
4, head cooling, severe RDS, NEC, Sepsis, Death 
 
3 
PATIENT ELIGIBILTY 
Subjects must meet all of the inclusion and exclusion criteria to be enrolled to the study. Study 
treatment may not begin until a subject is consented and randomized. 
3.1 Inclusion Criteria 
English-speaking 
≥ 16 years of age 
> 36 weeks gestation 
Singleton pregnancy 
Vertex presentation 
No contraindication to a vaginal delivery 
Meets at least one study criteria for prolonged labor: 
1. cervical dilation <6 cm after ≥12 hours with ruptured membranes and receiving 
oxytocin 
OR  
2. cervical dilation >6 cm and <1 cm dilation change over ≥2 hours with ruptured 
membranes and receiving oxytocin 
 
3.2 Exclusion Criteria 
Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for 
hypertension control 

 
7.26.21  
 
NCT04299438 
 
Receiving other beta blocker 
Maternal heart rate < 70 beats per minute, systolic blood pressure <90 mmHg, or 
diastolic blood pressure <50 mmHg on two sets of vital signs in the 1 hour prior to study 
drug administration: given that bradycardia and hypotension are possible side effects of 
propranolol 
History of any form of asthma: as this is a contraindication to beta blocker use 
Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in 
the neonate 
Any cardiac condition for which β blockade is contraindicated (cardiogenic shock, sinus 
bradycardia, and greater than first degree heart block) 
Known hypersensitivity to propranolol 
Intrauterine fetal demise since different labor protocols are used in these women 
Major fetal congenital anomaly since rate of cesarean may be inherently different in these 
women, unrelated to labor 
3.3 Vulnerable patient populations 
Pregnant women are considered a vulnerable population. As the condition of interest is a 
pregnancy-related and specific condition, it is unavoidable to exclude pregnant women from 
this research study. However, propranolol is currently used in clinical practice in pregnant 
women for other medical indications, so the risks to this population are minimally increased 
from that experienced in routine clinical care. 
 
Furthermore, neonates are considered a vulnerable population. We will be collecting data on 
neonates for our composite neonatal outcome. All risks to this vulnerable population will be 
minimal risk. Propranolol is a medication that is used clinically in the neonatal population for 
management of retinopathy of prematurity and hemangiomas. Neonatal risks of this study 
include the risk of neonatal hypoglycemia, respiratory depression, and bradycardia. Neonatal 
blood glucose screening is routine at HUP for all neonates whose mothers receive a β blocker 
intrapartum. Neonatal hypoglycemia is a rare but known side effect of intrapartum β blocker 
use. This occurs most commonly for women who receive labetalol intrapartum for blood 
pressure control. In one large study of over 2 million neonates, the rate of neonatal 
hypoglycemia was found to be 4.3% among those exposed to intrapartum β blockers, 
compared to 1.2% among controls. After adjusting for confounders, the odds ratio of neonatal 
hypoglycemia was found to be 1.68 [95% CI 1.50-1.89].9 National guidelines do not specify 
maternal use of β blockers as an indication for routine blood glucose monitoring in 
asymptomatic infants, but this is standard of care at UPHS, so all neonates included in this 
study will undergo routine hypoglycemia via heel stick at 3 time points within the first 24 hours 
of life. There are many risk factors for neonatal hypoglycemia and it is possible that these 
neonates would have required a glucose check regardless of enrolling in the study. In general, 
approximately 30% of all neonates born at term at UPHS meet criteria for glucose screening. 
The only additional risks to the neonate include chart review after delivery. Subjects will be 
made aware of these risks and that we will be collecting information on their neonates within 
the consent form. 
 
3.4 Ensuring Necessary Medical Interventions 

 
7.26.21  
 
NCT04299438 
 
Enrollment in this study will not alter any aspects of routine labor management. Continuous 
EFM and tocometry will occur on all patients in labor, consistent with standard of care. The 
remainder of clinical care in labor will be at the covering OB providers’ discretion. The 
frequency and timing of cervical examinations will occur per provider discretion. Standard 
treatment for GBS positive and GBS unknown patients will occur. The use of internal fetal 
monitoring and intrauterine pressure catheter will be at the discretion of the OB provider. 
Standard obstetric indications for cesarean delivery will be also be at the discretion of the OB 
provider. There will be no additional blood draws or cervical examinations for women enrolled 
in this study. 
 
3.5 Potential Benefit to Participants 
The potential benefit will be reduced risk of CD among individuals randomized to the 
intervention arm. This will lead to a possible reduction in maternal and neonatal morbidity 
associated with unscheduled CD. Additionally, the results of this study will benefit future 
patients in labor. All efforts will be taken to minimize the risks associated with this study and 
the risks overall are considered minimal; therefore, the risk to subjects is reasonable compared 
to the benefit to patients and to society in general.   
 
4 
TREATMENT ARMS 
4.1 Treatment Dosage and Administration 
▪ 
Propranolol hydrochloride 2mg IV 
• 
One possible repeat dose of 2mg IV given ≥2 hours later if <2 cm 
cervical dilation change over >2 hours on subsequent exam  
▪ 
Placebo – 2mL of 1% normal saline solution IV 
• 
One possible repeat dose of 2mL IV given ≥2 hours later if <2 cm 
cervical dilation change over >2 hours on subsequent exam  
4.2 Toxicities  
Any patient who receives treatment will be evaluated for toxicity. Each patient will be 
assessed for the development of toxicity according to vital sign monitoring or symptoms. In 
the event of developing bradycardia, hypotension, heart block, cardiogenic shock, 
bronchospasm, anaphylaxis, or signs of an allergic reaction, the second dose will not be 
administered.  
4.3 Concomitant Medications/Treatments 
All participants will be already receiving oxytocin for labor augmentation prior to receiving the 
study medication. No additional labor augmentation agents will be utilized. No additional β-
blocker, antihypertensive, or vasoactive medications will be utilized in conjunction with the 
study medication. 
4.4 Duration of Therapy 
All participants are eligible for a maximum of one repeat dose of the study medication, until 
they reach 10cm dilation or decision is made to proceed with cesarean delivery, whichever 
comes first. After this point, they will not be eligible for any further study medication.  
4.5 Duration of Follow Up 
Women/neonate dyads will be followed for the development of any maternal or neonatal 
complications through the duration of the postpartum hospital stay as well as for 
readmissions within 30 days of delivery. 
4.6 Removal of patients from protocol therapy 
Patients will be removed from therapy when any of the criteria listed in Section 4.2 and 5.5 
apply. The Principal Investigator will be notified and document the reason for study removal 

 
7.26.21  
 
NCT04299438 
 
and the date the patient was removed in the Case Report Form. The patient will be followed-
up per protocol.  
4.7 Blinding 
This is a double blind study and therefore physicians, staff, and patients will be blinded to the 
patient’s allocated treatment group. In the event of a potential suspected unexpected serious 
adverse reaction, unblinding will be undertaken by the PI. Unblinding may also be performed 
at the request of a senior clinician responsible for the care of a trial participant but such 
requests are likely to occur only in the case of an adverse clinical event and are expected to 
be rare.  Any request to unblind treatment allocation for clinical reasons will be made directly 
to IDS and the treatment allocation will be reported to the relevant clinician. The PI and main 
trial manager will be kept informed of all instances of unblinding but remain blind to treatment 
allocations themselves wherever possible. All requests for unblinding will be recorded by 
research staff and IDS.  
 
 
5 
STUDY PROCEDURES 
5.1 Screening for Recruitment and Recruitment Process 
Women meeting the criteria listed in section 3.1 will be invited to participate in the study and 
written informed consent will be obtained from those who choose to participate. The 
screening procedures include: 
• 
Informed Consent 
• 
Medical history: Complete medical and surgical history 
• 
Demographics: Age, gender, race, ethnicity 
• 
Review subject eligibility criteria 
• 
Review previous and concomitant medications 
• 
Physical exam including vital signs, height and weight 
• 
Vital signs (temperature, pulse, respirations, blood pressure), height, weight 
• 
Adverse event assessment: Baseline adverse events will be assessed. See 
section 6 for Adverse Event monitoring and reporting. 
 
5.2 Randomization 
Eligible, consented women will receive pre-randomized study medication. Study medications 
will be prepared and randomized by the Investigational Drug Service (IDS) via a random 
generated randomization scheme. The randomization scheme will be generated by a 
pharmacy associate within IDS not involved in the clinical care of the patient. Two single-use 
vials of the same medication – either propranolol or placebo- will be included in a numbered 
bag. One vial will be used for the first dose. If a patient meets eligibility criteria to receive a 
repeat dose, the second vial in the same bag will be used.  
 
5.3 Procedures During Treatment 
After study enrollment, the covering clinician will place an EPIC order for “investigational 
study drug” and will retrieve the next available pre-randomized study medication bag that will 
be available in the labor floor medication room. The number labeling the study medication 
bag will be recorded by the clinician and the patient’s identification label will be applied to the 
used vial of study medication after administration and returned to IDS for confirmation and 
record keeping. The time of administration of the study drug will be recorded by the patient’s 
nurse in EPIC. For a repeat dose of medication, the RN will use the second vial of medication 

 
7.26.21  
 
NCT04299438 
 
included in the same study medication packet, record the administration of the dose in EPIC, 
and label and return the medication to IDS in the same manner.  
 
Patients in both groups will undergo similar vital sign monitoring before and after each dose 
of study medication. Patients will have routine vital sign monitoring every 15-30 minutes 
depending on the stage of labor (including heart rate, blood pressure, and oxygen saturation 
assessment) through the duration of their enrollment in the study. 
The remainder of clinical care in labor and delivery will occur as per primary OB provider’s 
discretion as described in section 3.4. 
5.4 Follow-up Procedures 
During the postpartum hospital stay, women will continue to receive routine postpartum care 
at the discretion of their providers.  
5.5 Removal of Subjects from Study 
Patients can be taken off the study at any time at their own request, or they may be withdrawn at 
the discretion of the investigator for safety, behavioral or administrative reasons. The reason(s) 
for discontinuation will be documented and may include: 
• 
Patient voluntarily withdraws from treatment (follow-up permitted);  
• 
Patient withdraws consent (termination of treatment and follow-up); 
• 
Patient is unable to comply with protocol requirements; 
• 
Patient experiences toxicity that makes continuation in the protocol unsafe; 
• 
Treating physician judges continuation on the study would not be in the patient’s 
best interest. 
• 
The study is stopped. 
 
5.6 Protections Against Physical Risk 
There is minimal risk to the use of propranolol during labor. This medication is currently 
employed in clinical use in pregnant women, and other β-blocking medications such as 
labetalol are commonly used in laboring women in the University of Pennsylvania Health 
System. A DSMB comprised of individuals who are not investigators on the trial will be 
utilized to monitor for adverse outcomes. A list of mandatory events that should be reported 
to the DSMB within 24 hours of occurrence will be supplied to all clinicians and research 
coordinators managing trial patients. Also all serious adverse events will be recorded and 
reported to the institutional review board. 
 
5.7 Protection against Loss of Privacy/Breach of Confidentiality 
In order to protect a potential subject’s privacy, study staff will only approach potential 
subjects in a private setting. Once consented, we will take multiple steps to protect the study 
subject from breach of confidentiality. The list linking the subject’s name and medical record 
number will be kept behind the hospital firewall in a password-protected file. This file is only 
accessible through the hospital server to those individuals given password approval to 
access the file. Furthermore, the electronic database (REDCap) will be coded with a unique 
study identifier rather than with any individually identifiable private information. No PHI will be 
shared with anyone outside the institution.  
 

 
7.26.21  
 
NCT04299438 
 
6 
ADVERSE EVENTS 
6.1 Adverse Event Monitoring 
Adverse event data collection and reporting will be done to ensure the safety of subjects 
who will be enrolled in the study. Adverse events will be reported in a routine manner at 
scheduled times during the trial. Additionally, certain adverse events will be reported in an 
expedited manner to allow for optimal monitoring of patient safety and care.  
 
All patients experiencing an adverse event, regardless of its relationship to study 
drug/device, will be monitored until:  
➢ the adverse event resolves or the symptoms or signs that constitute the adverse 
event return to baseline;  
➢ any abnormal laboratory values have returned to baseline;  
➢ there is a satisfactory explanation other than the study drug for the changes 
observed; or 
➢ death. 
6.2 Definitions 
6.2.1 
Definition of Adverse Event 
An adverse event (AE) is any untoward medical occurrence in a patient receiving 
study treatment and which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of an experimental intervention, whether or not related to 
the intervention.  
For the purposes of this study, the following will be considered and adverse event:  
- 
Maternal bradycardia < 50 beats per minute within 30 minutes of drug 
administration 
- 
Maternal hypotension <80/40 mmHg within 30 minutes of drug 
administration 
- 
Maternal bronchospasm  
- 
Maternal hypoglycemia requiring treatment  
- 
Maternal allergic reaction  
- 
Chorioamnionitis 
- 
Endometritis  
- 
VTE 
- 
Blood transfusion 
- 
Readmission within 7 days 
- 
NICU admission > 48 hours  
6.2.2 Severity of Adverse Events 
The severity of an AE is graded as follows: 
Mild (grade 1): the event causes discomfort without disruption of normal daily 
activities. 

 
7.26.21  
 
NCT04299438 
 
Moderate (grade 2): the event causes discomfort that affects normal daily 
activities. 
Severe (grade 3): the event makes the patient unable to perform normal daily 
activities or significantly affects his/her clinical status. 
Life-threatening (grade 4): the patient was at risk of death at the time of the 
event. 
Fatal (grade 5): the event caused death. 
6.2.3 Serious Adverse Events 
A “serious” adverse event is defined in regulatory terminology as any untoward 
medical occurrence that: 
Results in death. 
If death results from (progression of) the disease, the disease should 
be reported as event (SAE) itself. 
Is life-threatening (i.e. the patient was at risk of death at the time of the event). 
Requires in-patient hospitalization or prolongation of existing hospitalization for ≥ 
24 hours. 
Results in persistent or significant disability or incapacity. 
Is an important medical event. Essentially, any event that does not meet the 
above criteria, but that in the judgment of the investigator jeopardizes the patient, 
may be considered for reporting as a serious adverse event.  
 
For the purposes of this study, the adverse events that would meet any of these 
criteria are listed below and will be documented and reported as a SAE. In 
addition, any unexpected event which the PI believes to have been cause or 
contributed to by the intervention, regardless of whether it resulted in 
hospitalization, will also be considered an AE or SAE.    
Maternal SAE: 
- 
Maternal death 
- 
ICU admission 
- 
Anaphylaxis 
- 
Hysterectomy 
Neonatal SAE:  
- 
Death 
- 
Blood transfusion 
- 
Hypoxic-ischemic encephalopathy (if NICU documents HIE as diagnosis) 
- 
Intraventricular hemorrhage Grade 3 or 4 
- 
Severe respiratory distress (intubation and mechanical ventilation for a 
minimum of 12 hours) 
- 
Necrotizing enterocolitis or rule out NEC (if NICU documents this) 
- 
Culture proven neonatal sepsis  
 

 
7.26.21  
 
NCT04299438 
 
6.3 Steps to Determine If an Adverse Event Requires Expedited Reporting 
Step 1: Identify the type of adverse event   
 
Step 2: Grade the adverse event  
 
Step 3: Determine whether the adverse event is related to the protocol therapy  
Attribution categories are as follows: 
- Definite – The AE is clearly related to the study treatment. 
- Probable – The AE is likely related to the study treatment. 
- Possible – The AE may be related to the study treatment. 
- Unrelated – The AE is clearly NOT related to the study treatment. 
 
Step 4:  
Determine the prior experience of the adverse event.  
Expected events are those that have been previously identified as resulting from 
administration of the agent. An adverse event is considered unexpected, for expedited 
reporting purposes only, when either the type of event or the severity of the event is not 
listed in: 
• 
the current known adverse events listed in the Agent Information Section of this 
protocol; 
• 
the drug package insert; 
• 
the current Investigator’s Brochure 
6.4 Reporting Requirements for Adverse Events 
6.4.1 
Expedited Reporting 
• 
The Principal Investigator will be notified within 24 hours of learning of any 
serious adverse events, regardless of attribution, occurring during the study 
or within 30 days of the last administration of the study drug.  
• 
The University of Pennsylvania IRB must be notified within 10 business 
days of “any unanticipated problems involving risk to subjects or others” 
(UPR/UPIRSO). 
The following events meet the definition of UPR: 
1. Any serious event (injuries, side effects, deaths or other problems), which 
in the opinion of the Principal Investigator was unanticipated, involved 
risk to subjects or others, and was possibly related to the research 
procedures. 
2. Any serious accidental or unintentional change to the IRB-approved 
protocol that alters the level of risk. 
3. Any deviation from the protocol taken without prior IRB review to 
eliminate apparent immediate hazard to a research subject. 

 
7.26.21  
 
NCT04299438 
 
4. Any new information (e.g., publication, safety monitoring report, updated 
sponsor safety report), interim result or other finding that indicates an 
unexpected change to the risk/benefit ratio for the research. 
5. Any breach in confidentiality that may involve risk to the subject or others. 
6. Any complaint of a subject that indicates an unanticipated risk or that 
cannot be resolved by the Principal Investigator. 
6.4.2 
Routine Reporting 
All other adverse events- such as those that are expected, or are unlikely or definitely not 
related to the study participation- are to be reported annually as part of regular data 
submission. 
6.5 Stopping Rules  
This study does not have a primary safety endpoint or place study subjects at high risk.  
7 
DRUG/DEVICE INFORMATION 
7.1 Propranolol hydrochloride  
• 
Other names for the drug: Inderal  
• 
Classification - type of agent: β-blocker, antiarrhythmic  
• 
Mode of action: Propranolol is a nonselective beta-adrenergic receptor blocking 
agent that specifically competes with beta-adrenergic receptor stimulating agents 
for available receptor sites, thereby decreasing chronotropic, inotropic, and 
vasodilator responses to beta-adrenergic stimulation. 
• 
Protocol dose: 2mg IV; one possible repeat dose ≥2 hours later 
• 
Route of administration for this study: IV push 
• 
Incompatibilities: there are no medications that are contraindicated for use with 
propranolol 
• 
Availability: commercially available, on formulary 
• 
Side effects: hypotension, congestive heart failure, bradycardia, heart block, 
cardiac arrest, bronchospasm, and cutaneous ulcers. (Please refer to the 
manufacturer’s package insert for a complete list of adverse events) 
• 
Nursing implications: Propranolol is excreted in breast milk.  
 
 
7.2 Product Preparation/Packaging, Receipt and Storage  
Investigational Drug Service (IDS) of the University of Pennsylvania will purchase commercial 
propranolol hydrochloride 2mg/mL vials. An internal lot number and use-by date will be 
assigned. Visually-matching placebo vials of normal saline 0.9% will be purchased by IDS. 
An internal lot number and use-by date will be assigned.  
 
IDS will dispense pre-randomized and numbered packets of study medication containing two 
doses of either propranolol or placebo medication. IDS will package and deliver the drugs to 
the locked labor floor medication room. Drug accountability will be maintained by IDS and 
study coordinators. 
 
Study medication and placebo will be stored at room temperature in the locked medication 
room on the labor floor only accessible by floor and research staff. 
 
8 
STUDY DESIGN/STUDY ENDPOINTS 

 
7.26.21  
 
NCT04299438 
 
This will be a prospective, double-bling, placebo-controlled, randomized, multi-center study on the 
effect of propranolol versus placebo on the rate of cesarean delivery for women with prolonged labor. 
Please refer to section 2.3 for endpoints.  
 
Regarding stopping rules for safety or efficacy, we do not anticipate early termination of the study for 
either. Issues that would be of concern would be persistent bradycardia or hypotension with therapy 
and unexpected events.  Other findings that could trigger a safety review include the number of SAEs 
overall, the number of occurrences of a particular type of SAE, severe AEs, or increased frequency of 
events. 
 
8.1 Sample Size and Accrual 
The sample size is based on the expected CD rate for women experiencing prolonged labor 
of approximately 45%. For a power of 80% and an alpha of 0.05, 326 women would be 
needed to find a decrease in rate of CD to 30%.  
 
We estimate 40 eligible women deliver at HUP per month. We anticipate approaching 80% of 
these women or approximately 32 per month. With an estimated 50% consent rate, we would 
enroll approximately 16 women per month. Therefore, we would need 24 months to reach our 
target enrollment of 326 women.  
 
8.2 Data Analyses Plans 
Measures of relative risk will include 95% confidence intervals. Descriptive statistics will be 
presented as mean with standard deviation, median with interquartile range, or proportion with 
95% confidence interval based on data type and distribution.  Comparisons between groups 
will be performed using a Chi-square or Fisher’s exact test for categorical variables and 
parametric or non-parametric tests for continuous variables, as appropriate. Intention-to-treat 
analyses will be conducted such that all patients with available follow-up measures will be 
included in the analysis. Statistical analyses were conducted in STATA, version 15.1 (College 
Station, Texas). Two-tailed P values of <0.05 will be considered statistically significant. 
9 
STUDY MANAGEMENT 
9.1 Conflict of Interest 
Any investigator who has a conflict of interest with this study (patent ownership, royalties, 
or financial gain greater than the minimum allowable by their institution, etc.) must have 
the conflict reviewed by the PI and the IRB.  All investigators will follow the University’s 
conflict of interest policy. 
9.2 Collection of data 
We will record data on each patient regarding their demographics, obstetrical and medical 
history, labor and delivery admission through postpartum discharge. We will also collect 
neonatal outcomes on their infants through hospital discharge. 
9.2.1 
Private information 
Only the study staff listed on the protocol approved by the Institutional Review Board will 
have access to individually identifiable private information about human subjects. The only 
individually identifiable private information about human subjects that will be collected for 
research purposes is the subject’s name and medical record number for the purpose of 
linking the subject to their unique study identifier. 

 
7.26.21  
 
NCT04299438 
 
9.2.2 
Data Protection 
The individually identifiable private information that will be collected is name and medical 
record number for the purposes on linking the subject to their unique study number for 
chart review. The file linking the study number to the name, medical record number and 
phone number will be kept in a password-protected file on a secure server. Data will be 
collected primarily by the research team. The electronic database (REDCap) will be stored 
behind the institution’s firewall in a password-protected file. 
9.3 Institutional Review Board (IRB) Approval and Consent  
It is expected that the IRB will have the proper representation and function in accordance 
with federally mandated regulations. The IRB should approve the consent form and 
protocol. 
In obtaining and documenting informed consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to Good Clinical Practice (GCP) 
and to ethical principles that have their origin in the Declaration of Helsinki. 
Before recruitment and enrollment onto this study, the patient will be given a full 
explanation of the study and will be given the opportunity to review the consent form. Each 
consent form must include all the relevant elements currently required by the FDA 
Regulations and local or state regulations. Once this essential information has been 
provided to the patient and the investigator is assured that the patient understands the 
implications of participating in the study, the patient will be asked to give consent to 
participate in the study by signing an IRB-approved consent form. Patients will not be 
approached for consent if clinical judgement deems them to be in an unclear state of mind 
(e.g. either due to excessive pain or from intravenous pain medication use).   
Prior to a patient’s participation in the trial, the written informed consent form should be 
signed and personally dated by the patient and by the person who conducted the informed 
consent discussion. 
9.4 
Data Management and Monitoring/Auditing 
9.4.1 
Data Safety and Monitoring Plan 
Safety monitoring will be performed periodically by the principal investigator. This will 
include assessment of accuracy of data recording, assuring de-identification of data, and 
that there is appropriate locked storage of data material. There will be no planned interim 
analyses. An advisory board will be created for continual oversight of the project. It will be 
comprised of faculty members within the department with extensive experience in 
prospective clinical trials. They will perform periodic reviews of safety data from this 
study. The DSMB that will be created is attached.  
9.5 
Adherence to the Protocol 
Except for an emergency situation in which proper care for the protection, safety, and 
well-being of the study patient requires alternative treatment, the study shall be 
conducted exactly as described in the approved protocol.  

 
7.26.21  
 
NCT04299438 
 
9.5.1 
Emergency Modifications 
Investigators may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to trial subjects without prior IRB approval.  
For any such emergency modification implemented, a IRB modification form must 
be completed within five (5) business days of making the change.  
9.5.2 
Other Protocol Deviations/Violations 
All other planned deviations from the protocol must have prior approval by the 
Principal Investigator and the IRB. According to the IRB, a protocol deviation is 
any unplanned variance from an IRB approved protocol that:  
• 
Is generally noted or recognized after it occurs 
• 
Has no substantive effect on the risks to research participants 
• 
Has no substantive effect on the scientific integrity of the research plan or the 
value of the data collected  
• 
Did not result from willful or knowing misconduct on the part of the 
investigator(s).  
 
An unplanned protocol variance is considered a violation if the variance: 
• 
Has harmed or increased the risk of harm to one or more research participants. 
• 
Has damaged the scientific integrity of the data collected for the study. 
• 
Results from willful or knowing misconduct on the part of the investigator(s). 
• 
Demonstrates serious or continuing noncompliance with federal regulations, 
State laws, or University policies. 
If a deviation or violation occurs without prior approval from the Principal 
Investigator, the ensuing guidelines will be followed: 
Protocol Deviations: Personnel will report to any sponsor or data and safety 
monitoring committee in accordance with their policies. Deviations should be 
summarized and reported to the IRB at the time of continuing review. 
Protocol Violations: Study personnel should report violations within one (1) week 
of the investigator becoming aware of the event using the same IRB online 
mechanism used to report Unanticipated Problems.  
9.6 Record Retention 
Study documentation includes all Case Report Forms, data correction forms or queries, 
source documents, monitoring logs/letters, and regulatory documents (e.g., protocol and 
amendments, IRB correspondence and approval, signed patient consent forms). 
Source documents include all recordings of observations or notations of clinical activities 
and all reports and records necessary for the evaluation and reconstruction of the clinical 
research study. 
Government agency regulations and directives require that the study investigator must 
retain all study documentation pertaining to the conduct of a clinical trial. In all other cases, 

 
7.26.21  
 
NCT04299438 
 
study documents should be kept on file until three years after the completion and final study 
report of this investigational study. 
9.7 Obligations of Investigators 
The Principal Investigator is responsible for the conduct of the clinical trial at the site in 
accordance with Title 21 of the Code of Federal Regulations and/or the Declaration of 
Helsinki. The Principal Investigator is responsible for personally overseeing the treatment 
of all study patients. The Principal Investigator must assure that all study site personnel, 
including sub-investigators and other study staff members, adhere to the study protocol 
and all FDA/GCP/NCI regulations and guidelines regarding clinical trials both during and 
after study completion. 
The Principal Investigator will be responsible for assuring that all the required data will be 
collected and entered onto the Case Report Forms. Periodically, monitoring visits will be 
conducted and the Principal Investigator will provide access to his/her original records to 
permit verification of proper entry of data. At the completion of the study, all case report 
forms will be reviewed by the Principal Investigator and will require his/her final signature 
to verify the accuracy of the data. 
 
10 References  
1. 
Obstetric care consensus no. 1: safe prevention of the primary cesarean delivery. Obstet 
Gynecol. 2014;123(3):693-711. 
2. 
Mahon WA, Reid DW, Day RA. The in vivo effects of beta adrenergic stimulation and blockade on 
the human uterus at term. J Pharmacol Exp Ther. 1967;156(1):178-185. 
3. 
Sanchez-Ramos L, Quillen MJ, Kaunitz AM. Randomized trial of oxytocin alone and with 
propranolol in the management of dysfunctional labor. Obstet Gynecol. 1996;88(4 Pt 1):517-
520. 
4. 
Direkvand-Moghadam A, Jaafarpour M, Khani A, Taheri S, Delpisheh A. The effect of oral 
propranolol plus oxytocin versus oxytocin only on the process and outcome of labor: A double-
blind randomized trial. Iran J Nurs Midwifery Res. 2014;19(5):491-495. 
5. 
Cilliers J. A randomised clinical trial to determine the effect of beta-adrenergic blocking with 
propranolol on labour. South African Journal of Obstetrics and Gynaecology 2013;19(2):53-55. 
6. 
Kashanian M, Fekrat M, Zarrin Z, Ansari NS. A comparison between the effect of oxytocin only 
and oxytocin plus propranolol on the labor (a double blind randomized trial). J Obstet Gynaecol 
Res. 2008;34(3):354-358. 
7. 
Palomaki O, Uotila J, Tammela O, et al. A double blind, randomized trial on augmentation of 
labour with a combination of intravenous propranolol and oxytocin versus oxytocin only. Eur J 
Obstet Gynecol Reprod Biol. 2006;125(1):44-49. 
8. 
Adamsons K, de la Vega A, Santiago P. Reduction in the cesarean section rate in nulliparous 
patients after administration of intravenous propranolol. P R Health Sci J. 1999;18(1):5-8. 
9. 
Bateman BT, Patorno E, Desai RJ, et al. Late Pregnancy beta Blocker Exposure and Risks of 
Neonatal Hypoglycemia and Bradycardia. Pediatrics. 2016;138(3).